Targeted gene sequencing panels: Applicability for neoantigen profiling of colon and rectal adenocarcinoma
Канyгина А. В., Шарова Е. И., Султанов Р. И., Счелyгин Y. А., Долудин Ю. В., Кострюкова Е. С., Генерозов Е. В.
Биомедицинская химия
Т. 64, Вып. 6, С. 517-524
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.18097/PBMC20186406517
Аннотация:
Cancer immunotherapy represents a promising and rapidly developing approach for the treatment of oncological diseases. Among the methods of personalized adjuvant immunotherapy, neoantigenic peptide-based drugs have demonstrated substantial efficiency. These drugs are designed to target mutant proteins arising from somatic alterations in the genome of tumor cells and thus stimulate immune response against tumor tissues. The methods of individual screening for potentially immunogenic mutations are mostly based on next-generation exome sequencing of tumor samples, which is a complex and costly procedure for clinical application. Targeted gene sequencing panels limited to a certain set of genes represent a reasonable alternative to WES. Targeted sequencing is also more efficient when there is a low amount of the sample DNA available. We have estimated the potential efficiency of targeted oncological panels in terms of somatic neoantigen profiling in colorectal cancer (colon and rectal aden
Ключевые слова:
Colorectal cancer; Immunotherapy; Neoantigens; Sequencing; Targeted panels
adenocarcinoma; colorectal tumor; exome; genetics; high throughput sequencing; human; mutation; Adenocarcinoma; Colorectal Neoplasms; Exome; High-Throughput Nucleotide Sequencing; Humans; Mutation
Язык текста: Русский
ISSN: 2310-6905
Канyгина А. В.
Шарова Е. И.
Султанов Р. И.
Счелyгин Y. А.
Долудин Ю. В. Юрий Валерьевич 1987-
Кострюкова Е. С.
Генерозов Е. В.
Kanygina A. V.
Sharova E. I.
Sultanov R. I.
Schelygin Y. A.
Doludin Yu. V. Yurij Valeryevich 1987-
Kostryukova E. S.
Generozov E. V.
Targeted gene sequencing panels: Applicability for neoantigen profiling of colon and rectal adenocarcinoma
Текст визуальный непосредственный
Биомедицинская химия
Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича
Т. 64, Вып. 6 С. 517-524
2018
Статья
Colorectal cancer Immunotherapy Neoantigens Sequencing Targeted panels
adenocarcinoma colorectal tumor exome genetics high throughput sequencing human mutation Adenocarcinoma Colorectal Neoplasms Exome High-Throughput Nucleotide Sequencing Humans Mutation
Cancer immunotherapy represents a promising and rapidly developing approach for the treatment of oncological diseases. Among the methods of personalized adjuvant immunotherapy, neoantigenic peptide-based drugs have demonstrated substantial efficiency. These drugs are designed to target mutant proteins arising from somatic alterations in the genome of tumor cells and thus stimulate immune response against tumor tissues. The methods of individual screening for potentially immunogenic mutations are mostly based on next-generation exome sequencing of tumor samples, which is a complex and costly procedure for clinical application. Targeted gene sequencing panels limited to a certain set of genes represent a reasonable alternative to WES. Targeted sequencing is also more efficient when there is a low amount of the sample DNA available. We have estimated the potential efficiency of targeted oncological panels in terms of somatic neoantigen profiling in colorectal cancer (colon and rectal aden